Ondansetron hydrochloride dihydrate
Based on 11 publication(s) in Google Scholar
Ondansetron (GR 38032; SN 307) hydrochloride dehydrate is a highly selective 5-HT3 receptor antagonist with an IC50 value of 103 pM. Ondansetron hydrochloride dehydrate exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron hydrochloride dehydrate can inhibit nausea and vomiting induced by chemotherapy and radiotherapy.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 103639-04-9
- Formula: C18H24ClN3O3
- Molecular Weight:365.85
-
Storage:
4°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-17394
Cisplatin
-
HY-15141
Staurosporine
-
HY-14648
Dexamethasone
-
HY-17031
SBE-β-CD
-
HY-B0071A
Granisetron Hydrochloride
-
HY-B0387
Ibutilide fumarate
-
HY-12719
Dexmedetomidine
-
HY-B0006
Carvedilol
-
HY-B0020
Tropisetron Hydrochloride
-
HY-B0002AR
Ondansetron hydrochloride dihydrate (Standard)
-
HY-14541
Olanzapine
-
HY-B0006R
Carvedilol (Standard)
Publications Citing Use of MedChemExpress (MCE) Ondansetron hydrochloride dihydrate
More- Adv Sci (Weinh). 2025 Jul;12(26):e2503739. [Abstract]
- J Ethnopharmacol. 2024 Apr 6:323:117703. [Abstract]
- Int J Pharm. 2015 Dec 30;496(1):33-41. [Abstract]
- Front Pharmacol. 2024 Aug 21:15:1443169. [Abstract]
- Eur J Pharm Sci. 2023 Aug 1:187:106475. [Abstract]
- Biomedicines. 2026 May 3;14(5):1040. [Abstract]
- Prog Neuropsychopharmacol Biol Psychiatry. 2023 Mar 2:122:110689. [Abstract]
- J Radiat Res Appl Sci. 2023 Dec, 16(4), 100682.
- Biochem Biophys Res Commun. 2025 Oct 30:786:152756. [Abstract]
- SSRN. 2023 Srep 5.
- Patent. US20170319486A1.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
IHC
All 5-HT Receptor Isoforms
More
Biological Activity
|
5-HT3 Receptor |
Ondansetron (2 mg/kg; i.p.; six consecutive days) hydrochloride dehydrate exhibits anti-inflammatory effects in rats through the 5-HT3 receptor[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 103639-04-9
-
Appearance Solid
-
Molecular Weight 365.85
-
Formula C18H24ClN3O3
-
Color White to off-white
-
SMILES
O=C1C(CN2C=CN=C2C)CCC(N3C)=C1C4=C3C=CC=C4.[H]Cl.O.O
-
Synonyms
GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
The Locus Coeruleus-Periaqueductal Gray GABAergic Projection Regulates Comorbid Pain and Depression. [Abstract]2025 Jul;12(26):e2503739. PMID: 40192524 -
J Ethnopharmacol
Phytomedicine Fructus Aurantii-derived two absorbed compounds unlock antidepressant and prokinetic multi-functions via modulating 5-HT3/GHSR. [Abstract]2024 Apr 6:323:117703. PMID: 38185260
Ondansetron hydrochloride dihydrate purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 Apr 6:323:117703. [Abstract]
Ondansetron (1 mg/kg; IP) had no impact on immobility time compared with the model group in rats.
Ondansetron hydrochloride dihydrate purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 Apr 6:323:117703. [Abstract]
Ondansetron (1 mg/kg; IP) alone did not affect GE (gastric emptying) and IT (intestinal transit), overturning the gastrointestinal efficacy of hesperidin (MH).
Ondansetron hydrochloride dihydrate purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 Apr 6:323:117703. [Abstract]
Ondansetron (1 mg/kg; IP) reversed the rise in 5-HT3 compared to the hesperidin (MH) group (68.42 ± 4.05 vs 78.85 ± 3.28 ng/mL).
-
Int J Pharm
Formulation and development of pH-independent/dependent sustained release matrix tablets of ondansetron HCl by a continuous twin-screw melt granulation process. [Abstract]2015 Dec 30;496(1):33-41. PMID: 25863118 -
Front Pharmacol
The therapeutic targets and signaling mechanisms of ondansetron in the treatment of critical illness in the ICU. [Abstract]2024 Aug 21:15:1443169. PMID: 39234104 -
Eur J Pharm Sci
Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes. [Abstract]2023 Aug 1:187:106475. PMID: 37225005 -
Biomedicines
Ferroptosis in Septic Cardiomyopathy Is Alleviated by Ondansetron: The Critical Role of the HTR3A-ATF3 Axis in Mitochondrial and Oxidative Homeostasis. [Abstract]2026 May 3;14(5):1040. PMID: 42193366 -
Prog Neuropsychopharmacol Biol Psychiatry
Baicalein exerts anxiolytic and antinociceptive effects in a mouse model of posttraumatic stress disorder: Involvement of the serotonergic system and spinal delta-opioid receptors. [Abstract]2023 Mar 2:122:110689. PMID: 36462602 -
Ondansetron hydrochloride dihydrate purchased from MedChemExpress. Usage Cited in: J Radiat Res Appl Sci. 2023 Dec, 16(4), 100682.
Ondansetron (ODN; 2 mg/kg; subcutaneously; 0-120 min) produced significant analgesia in both the Tail flick (TF) and hot plate (HP) tests compared with saline in rats.
Ondansetron hydrochloride dihydrate purchased from MedChemExpress. Usage Cited in: J Radiat Res Appl Sci. 2023 Dec, 16(4), 100682.
Ondansetron (ODN; 2 mg/kg; subcutaneously) decreased 5-HT3A immunoreactivity in rats dorsal root ganglia.
-
Biochem Biophys Res Commun
Dual-cardiotoxicity evaluation of torsadogenic risk drugs using human iPSC-derived cardiomyocytes. [Abstract]2025 Oct 30:786:152756. PMID: 41043280 -
-
Solvent & Solubility
DMSO : 100 mg/mL (273.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 16.67 mg/mL (45.57 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
-
Handling Instructions (2659 KB)
References
[1]. Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). J Physiol. 1998 Mar 15;507 ( Pt 3):653-65. [Content Brief]
[2]. Barann M, et al. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):255-65. [Content Brief]
[3]. Wildeboer KM, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009 Dec 1;1300:41-50. [Content Brief]
[4]. Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20(6):1103-16. [Content Brief]
[5]. Umathe SN, et al. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20(1):78-83. [Content Brief]
[6]. Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12(3):421-31. [Content Brief]
[7]. Xin Wang, et al. Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. Cell Biochem Biophys. 2015 Jun;72(2):471-3. [Content Brief]
[8]. Azadeh Motavallian-Naeini, et al. Anti-inflammatory effect of ondansetron through 5-HT3 receptors on TNBS-induced colitis in rat. EXCLI J2012 Feb 22:11:30-44. eCollection 2012. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.7334 mL | 13.6668 mL | 27.3336 mL | 68.3340 mL |
| 5 mM | 0.5467 mL | 2.7334 mL | 5.4667 mL | 13.6668 mL | |
| 10 mM | 0.2733 mL | 1.3667 mL | 2.7334 mL | 6.8334 mL | |
| 15 mM | 0.1822 mL | 0.9111 mL | 1.8222 mL | 4.5556 mL | |
| 20 mM | 0.1367 mL | 0.6833 mL | 1.3667 mL | 3.4167 mL | |
| 25 mM | 0.1093 mL | 0.5467 mL | 1.0933 mL | 2.7334 mL | |
| 30 mM | 0.0911 mL | 0.4556 mL | 0.9111 mL | 2.2778 mL | |
| 40 mM | 0.0683 mL | 0.3417 mL | 0.6833 mL | 1.7084 mL | |
| DMSO | 50 mM | 0.0547 mL | 0.2733 mL | 0.5467 mL | 1.3667 mL |
| 60 mM | 0.0456 mL | 0.2278 mL | 0.4556 mL | 1.1389 mL | |
| 80 mM | 0.0342 mL | 0.1708 mL | 0.3417 mL | 0.8542 mL | |
| 100 mM | 0.0273 mL | 0.1367 mL | 0.2733 mL | 0.6833 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Ondansetron hydrochloride dihydrate Related Classifications
HY-B0002A Related Classifications
Powered by Bioz